Chemotherapy_with_high_dose_ifosfamide/mesna_plus_cisplatin_for_the_treatment_of_ovarian_cancer:_a_study_of_the_Grupo_de_Estudio_y_Tratamiento_Latino-Americano_del_Cancer._Twenty-one_evaluable_patients_with_FIGO_stages_II-IV_epithelial_ovarian_cancer,_median_age_57_(range_47-75_years),_were_treated_with_ifosfamide_(IF),_3_g/m2_diluted_in_500_ml_saline_solution,_8_hour_intravenous_(i.v.)_infusion_on_days_1-5;_mesna_20%_of_IF_dose,_i.v._bolus_injection,_was_given_at_hours_0_and_4;_mesna_40%_of_IF_dose_by_oral_route_at_hours_8_and_12,_days_1-5;_plus_cisplatin_20_mg/m2_diluted_in_500_ml_saline_solution,_2_hour_i.v._infusion,_days_1-5._Cycles_were_repeated_every_4_weeks._All_patients_had_metastatic_lesions_(mesentery,_pleura,_colon,_cervix,_abdominal_wall,_lung,_liver,_bladder,_and_nodes)._Toxicity_ranged_from_mild_to_moderate._All_patients_experienced_alopecia,_nausea,_and_vomiting._Neutropenia_and_anemia_ranged_from_mild_to_moderate._One_patient_experienced_mild_brain_confusion_and_two_patients_microscopic_hematuria._Ten_clinically_complete_responses_(47%)_and_five_clinically_partial_responses_(23%)_were_registered,_for_an_overall_70%_objective_response._However,_after_a_second_look_performance_in_10_patients_with_clinically_complete_response,_six_of_10_patients_showed_a_pathological_complete_response_and_four_showed_pathological_partial_response._The_median_duration_of_complete_response_is_about_33_months,_and_median_partial_response_duration_is_14_months._Although_the_numbers_are_small,_these_data_indicate_that_combination_chemotherapy_with_high_dose_ifosfamide/mesna_plus_cisplatin_may_be_an_active_treatment_for_advanced_ovarian_carcinoma.